Alzex Neuropharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	2006
Period Ending	Dec '11 Dec 31, 2011	Dec '10 Dec 31, 2010	Dec '09 Dec 31, 2009	Dec '08 Dec 31, 2008	Dec '07 Dec 31, 2007	2006
Operating Revenue	4.72	3.78	8.79	14.97	15.13	Upgrade
Other Revenue	0.01	0.04	0.01	0.02	-	Upgrade
Revenue	4.73	3.82	8.8	14.98	15.13	Upgrade
Revenue Growth (YoY)	23.83%	-56.58%	-41.24%	-0.94%	6.09%	Upgrade
Cost of Revenue	4.3	3.37	7.34	12.68	3.74	Upgrade
Gross Profit	0.43	0.45	1.46	2.3	11.39	Upgrade
Selling, General & Admin	0.35	0.27	0.96	1.43	0.69	Upgrade
Research & Development	-	-	-	-	0.37	Upgrade
Amortization of Goodwill & Intangibles	0.06	0.06	0.06	-	-	Upgrade
Other Operating Expenses	-	-	0.7	1.09	10.62	Upgrade
Operating Expenses	0.49	0.34	1.74	2.51	11.73	Upgrade
Operating Income	-0.06	0.11	-0.27	-0.21	-0.34	Upgrade
Interest Expense	-0.01	-0.03	-0.06	-0.07	-0.07	Upgrade
Other Non Operating Income (Expenses)	0.1	-	-	0.5	0.05	Upgrade
Pretax Income	0.03	0.08	-0.33	0.22	-0.36	Upgrade
Net Income	0.03	0.08	-0.33	0.22	-0.36	Upgrade
Net Income to Common	0.03	0.08	-0.33	0.22	-0.36	Upgrade
Net Income Growth	-59.83%	-	-	-	-	Upgrade
Free Cash Flow	0.29	0.07	-0.24	0.34	1.32	Upgrade
Gross Margin	9.09%	11.85%	16.63%	15.37%	75.30%	Upgrade
Operating Margin	-1.17%	2.95%	-3.08%	-1.40%	-2.23%	Upgrade
Profit Margin	0.68%	2.09%	-3.75%	1.49%	-2.35%	Upgrade
Free Cash Flow Margin	6.05%	1.88%	-2.71%	2.29%	8.75%	Upgrade
EBITDA	0.01	0.18	-0.26	-0.18	-0.33	Upgrade
EBITDA Margin	0.19%	4.80%	-2.99%	-1.23%	-2.17%	Upgrade
D&A For EBITDA	0.06	0.07	0.01	0.03	0.01	Upgrade
EBIT	-0.06	0.11	-0.27	-0.21	-0.34	Upgrade
EBIT Margin	-1.17%	2.95%	-3.08%	-1.40%	-2.23%	Upgrade
Revenue as Reported	4.73	3.82	8.8	14.98	15.13	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.